- Policy
- Hanmi's Cossac was voluntarily withdrawn
- by Lee, Tak-Sun Jun 26, 2020 06:23am
- Cossac, which was once a representative medicine of sinus cold, disappeared. It was predicted when Hanmi switched marketing to 'Cossac-L', an upgraded item when it switched to Pseudoephedrine combination drug. However, since products converted to precription drugs at that time did not recover sales during OTC, it is understood that the re-
- Policy
- Penalty on 14 drug companies failed to report serialization
- by Lee, Hye-Kyung Jun 26, 2020 06:20am
- 14 pharmaceutical manufacturers and importers are facing administrative actions for neglecting serialization reporting mandate. Penalties on the nine out of 23 companies announced initially were dropped as the authority accepted their appeals. According to the ‘2019 Semi-annual Report on Manufacturer and Importer Subject to Administrati
- Policy
- The goal is to develop a corona vaccine in next year
- by Lee, Jeong-Hwan Jun 26, 2020 06:20am
- The Ministry of Health and Welfare said it was supporting a domestic COVID-19 vaccine with the goal of developing in the second half of next year and in 2022. Corona vaccines such as MERS and SARS were not developed because of the low global demand for vaccines. On the 24th, the MOHW replied to the written question of Nam In-soon, Democra
- Policy
- COVID-19 global clinical growth rate is about 17 times
- by Kim, Jung-Ju Jun 25, 2020 06:31am
- The global clinical trial of 'COVID-19' is steadily increasing. The increase rate is close to 17 times from March to the present. 15 cases have been approved in Korea, and research is actively underway, and as a whole, clinical trials of plasma devices using plasma of cured patients have surged 36 times. According to the trend of domestic and
- Policy
- The addition of Lipiodol will end in next May
- by Kim, Jung-Ju Jun 24, 2020 11:07am
- Lipiodol (Iodized oil) was lowered by 30% due to the government's authority adjustment, and was confirmed until the end of the addition. This is because Fattiodol by Dongkook has been released. Anagre by Yuhan and Agrylin by Shire Plc have secured the same number of products, and the surplus, which has been retained since the end of the secon
- Policy
- Promote to fast track bill for innovative companies
- by Lee, Jeong-Hwan Jun 24, 2020 06:14am
- Legislation is being put in place to give special cases of 'fast tracks' that speed up the approval and review process for new drugs developed by innovative pharmaceutical companies. The goal is to revitalize new drug development, grow innovation, and create jobs. On the 22nd, Ki Dongmin, a member of Democratic Party of Korea announced
- Policy
- Reimbursement cut on prescribing multiple low-dose Verzenio
- by Lee, Hye-Kyung Jun 24, 2020 06:13am
- The healthcare benefit would be cut for prescribing multiple unit of Lilly Korea’s Verzenio 50 mg, instead of 100 mg or 150 mg doses. Both of Verzenio’s low and high-dose tablets are priced at 49,587 won, and more reimbursement is paid out on prescribing two 50 mg tablets instead or one 100 mg tablet or prescribing three 50 mg tablets
- Policy
- HIRA clarifies coverage standard of Imfinzi following CCRT
- by Lee, Hye-Kyung Jun 23, 2020 06:21am
- To receive healthcare reimbursement when using AstraZeneca’s immunotherapy Imfinzi (durvalumab), a patient has to receive platinum-based concurrent chemoradiotherapy (CRT). Affected patients should be aware that the reimbursement benefit would not be provided for using Imfinzi after using sequential CRT or induction chemotherapy. K
- Policy
- Minister Choi said, COVID-19 treatment may come out
- by Lee, Jeong-Hwan Jun 23, 2020 06:20am
- Choi Kiyoung, Minister of Science and ICT, said that as soon as possible, COVID-19 treatment could be developed within two months. Minister Choi said that the development of treatments through the ‘drug repositioning method’ to discover the effect of COVID-19 treatment of already-approved drugs has been revealed, not through the approval
- Policy
- Generic for Daxas was applied
- by Lee, Tak-Sun Jun 23, 2020 06:20am
- Generic for Daxas (Roflumilast, AZ), which was approved in Korea, was first applied. Particularly, the generic that has been applied are noted because they also contain low doses (250 mcg). According to the MFDS on the 19th, Generics for DAXAS (Roflumilast), were applied for approval as of the 5th and notified to patent holder AstraZeneca.
